Yıl: 2022 Cilt: 15 Sayı: 3 Sayfa Aralığı: 611 - 618 Metin Dili: İngilizce DOI: 10.31362/patd.1117026 İndeks Tarihi: 19-04-2023

How has the COVID-19 disease affected patients with kidney stones?

Öz:
Purpose: To evaluate the relationship between the presence of kidney stones and COVID-19.Materials and methods: Patients, who were treated for COVID-19 as outpatients as well as inpatients in the ward and/or ICU of two different secondary and tertiary care centers between July 15, 2020, and December 31, 2020, and aged ≥18 years were retrospectively evaluated. The patients were divided into two subgroups based on the presence of kidney stones, and then the patients with kidney stone were categorized into three groups: those who were treated in an outpatient setting (Group 1), those who were treated in the ward (Group 2), and those who were treated in the intensive care unit (Group 3).Results: The total of 1,335 COVID-19 patients included in the study. Kidney stone was present in 31 (6.9%) of 450 outpatients, 41 (8.9%) of 460 inpatients treated in the ward, and 60 (14.1%) of 425 inpatients treated in the intensive care unit. In Group 1, the duration of COVID-19 treatment was significantly longer in patients with kidney stone than patients without kidney stone (8.1±1.7 vs. 6.8±2.2 days, p=0.01). In Group 2 and in Group 3, the mean hospitalization duration was significantly longer in patients with kidney stone than in those without kidney stone (9.1±3.7 vs. 6.2±2.1 days, p=0.007; 19.1±8.1 vs. 11.3±6.2 days, p=0.001, respectively). Conclusion: The duration of COVID-19 treatment was longer and the COVID-19 infection was more severe in those with kidney stones.
Anahtar Kelime: COVID-19 kidney stone nephrolithiasis pandemic

COVID-19 hastalığı böbrek taşı olan hastaları nasıl etkiledi?

Öz:
Amaç: Böbrek taşı varlığı ile COVID-19 hastalığı arasındaki ilişkinin değerlendirilmesiGereç ve yöntem: COVID-19 tanısı ile 15 Kasım-31 Aralık 2020 tarihleri arasında 2. ve 3. basamak 2 farklı merkezde ayaktan, servis ve/veya yoğun bakımda tedavi uygulanan hastalar retrospektif olarak tarandı. Öncelikle hastalar böbrek taşı varlığına göre alt gruplara ayrıldı ve daha sonra böbrek taşı olan olgular, ayaktan tedavi gören hastalar Grup 1, serviste yatarak tedavi gören hastalar Grup 2 ve yoğun bakımda tedavi ihtiyacı doğan olgular ise Grup 3 olarak kategorize edildi.Bulgular: Çalışmaya toplam 1335 COVID-19 hastası dahil edildi. Ayaktan tedavi edilen 450 hastanın 31'inde (%6,9), serviste yatan 460 hastanın 41'inde (%8,9) ve yoğun bakımda yatan 425 hastanın 60'ında (%14,1) böbrek taşı mevcuttu. Grup 1'de, böbrek taşı olan hastalarda COVID-19 tedavi süresi böbrek taşı olmayan hastalara göre anlamlı olarak daha uzundu (8,1±1,7 ve 6,8±2,2 gün, p=0,01). Grup 2 ve Grup 3'te ortalama hastanede kalış süresi böbrek taşı olan hastalarda böbrek taşı olmayanlara göre anlamlı olarak daha uzundu (sırasıyla 9,1±3,7 ve 6,2±2,1 gün, p=0,007; 19,1±8,1 ve 11,3±6,2 gün, p=0,001).Sonuç: Böbrek taşı olanlarda COVID-19 tedavi süresinin daha fazla ve COVID-19 enfeksiyonunun daha şiddetli olduğu saptandı.
Anahtar Kelime: COVID-19 Böbrek taşı nefrolitiazis pandemi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Erensoy S. SARS-CoV-2 and microbiological diagnostic dynamics in covıd-19 pandemic. Mikrobiyol Bul 2020;54:497-509. https://doi.org/10.5578/mb.69839
  • 2. Krishnan A, James P, Hamilton JP, Alqahtani SA, Woreta TA. A narrative review of coronavirus disease 2019 (COVID-19): clinical, epidemiological characteristics, and systemic manifestations. Intern Emerg Med 2021;16:815-830. https://doi.org/10.1007/ s11739-020-02616-5
  • 3. Mehta P, McAuley DF, Brownet M, al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
  • 4. Yoshikawa T, Hill T, Li K, Peters CJ, Tsenget CTK, et al. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J Virol 2009;83:3039-3048. https://doi. org/10.1128/JVI.01792-08
  • 5. Yuki, K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol 2020;215:108427. https://doi.org/10.1016/j. clim.2020.108427
  • 6. Pirola CJ, Sookoian S. Age but not sex may explain the negative effect of arterial hypertension and diabetes on COVID-19 prognosis. J Infect 2020;81:647-679. https://doi.org/10.1016/j.jinf.2020.05.010
  • 7. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R, et al. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol 2020;11:1446. https://doi. org/10.3389/fimmu.2020.01446
  • 8. López Lluch G, Santos Ocaña C, Sánchez Alcázar JA, et al. Mitochondrial responsibility in ageing process: innocent, suspect or guilty. Biogerontology 2015;16:599-620. https://doi.org/10.1007/s10522-015- 9585-9
  • 9. Moreno Fernández Ayala DJ, Navas P, López Lluch G. Age-related mitochondrial dysfunction as a key factor in COVID-19 disease. Exp Gerontol 2020;142:111147. https://doi.org/10.1016/j.exger.2020.111147
  • 10. Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y, et al. Epidemiology of stone disease across the world. World Journal of Urology 2017;35:1301-1320. https://doi.org/10.1007/s00345- 017-2008-6
  • 11. Scales CD, Smith AC, Hanley JM, Saigal CS, Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol 2012;62:160-165. https://doi.org/10.1016/j.eururo.2012.03.052
  • 12. Patel M, Yarlagadda V, Adedoyin O, et al. Oxalate induces mitochondrial dysfunction and disrupts redox homeostasis in a human monocyte derived cell line. Redox Biol, 2018;15:207-215. https://doi.org/10.1016/j. redox.2017.12.003
  • 13. de Lucena TMC, Santos AFS, Lima BR, Albuquerque Borborema ME, Silvaet JA. Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr 2020;14:597-600. https://doi. org/10.1016/j.dsx.2020.05.025
  • 14. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-733. https://doi.org/10.1056/ NEJMoa2001017
  • 15. Darisipudi MN, Knauf F. An update on the role of the inflammasomes in the pathogenesis of kidney diseases. Pediatr Nephrol 2016;31:535-544. https:// doi.org/10.1007/s00467-015-3153-z
  • 16. Joosten LAB, Crişan TO, Bjornstad P, Johnson RJ. Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev Rheumatol 2020;16:75-86. https://doi.org/10.1038/s41584-019- 0334-3
  • 17. Mulay SR, Evan A, Anders HJ. Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrol Dial Transplant 2014;29:507-514. https://doi.org/10.1093/ ndt/gft248
  • 18. Zeng G, Mai Z, Xia S, et al. Prevalence of kidney stones in China: an ultrasonography based cross- sectional study. BJU Int 2017;120:109-116. https://doi. org/10.1111/bju.13828
  • 19. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2- mediated ınflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin 2020;35:266- 271. https://doi.org/10.1007/s12250-020-00207-4
  • 20. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev 2020;19:102523. https://doi.org/10.1016/j. autrev.2020.102523
  • 21. Ferri C, Giuggioli D, Raimondo V, et al. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol 2020;39:3195-3204. https://doi.org/10.1007/s10067- 020-05334-7
  • 22. Popa IV, Diculescu M, Mihai C, Cijevschi Prelipcean C, Burlacu A. COVID-19 and inflammatory bowel diseases: risk assessment, shared molecular pathways, and therapeutic challenges. Gastroenterol Res Pract 2020;2020:1918035. https://doi. org/10.1155/2020/1918035
  • 23. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287- 2293. https://doi.org/10.1002/art.10524
  • 24. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007;66:308-312. https://doi.org/10.1136/ ard.2006.057265
  • 25. Başer HY, Başer A. The impact of the COVID-19 pandemic on the short and mid-term urological emergencies and the emergency department. J Exp Clin Med 2021;38:466-470. https://doi.org/10.52142/ omujecm.38.4.12
  • 26. Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med 2013;158:535-543. https://doi.org/10.7326/0003-4819- 158-7-201304020-00005
  • 27. Holmes RP, Assimos DG. The impact of dietary oxalate on kidney stone formation. Urol Res 2004;32:311-316. https://doi.org/10.1007/s00240-004-0437-3
  • 28. Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. Cell 2012;148:1145-1159. https://doi. org/10.1016/j.cell.2012.02.035
  • 29. Khan SR. Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis. Transl Androl Urol, 2014;3:256-276. https://doi.org/10.3978/j.issn.2223- 4683.2014.06.04
  • 30. Williams J, Holmes RP, Assimos DG, Mitchell T. Monocyte mitochondrial function in calcium oxalate stone formers. Urology 2016;93:224(e1-6). https://doi. org/10.1016/j.urology.2016.03.004
  • 31. Meftahi GH, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of “inflame-aging”. Inflamm Res 2020;69:825-839. https://doi.org/10.1007/s00011-020- 01372-8
APA DURAN M, Senel S, Izci Duran T, YIKILMAZ T, toksoz s (2022). How has the COVID-19 disease affected patients with kidney stones?. , 611 - 618. 10.31362/patd.1117026
Chicago DURAN Mesut Berkan,Senel Samet,Izci Duran Tugba,YIKILMAZ Taha Numan,toksoz serdar How has the COVID-19 disease affected patients with kidney stones?. (2022): 611 - 618. 10.31362/patd.1117026
MLA DURAN Mesut Berkan,Senel Samet,Izci Duran Tugba,YIKILMAZ Taha Numan,toksoz serdar How has the COVID-19 disease affected patients with kidney stones?. , 2022, ss.611 - 618. 10.31362/patd.1117026
AMA DURAN M,Senel S,Izci Duran T,YIKILMAZ T,toksoz s How has the COVID-19 disease affected patients with kidney stones?. . 2022; 611 - 618. 10.31362/patd.1117026
Vancouver DURAN M,Senel S,Izci Duran T,YIKILMAZ T,toksoz s How has the COVID-19 disease affected patients with kidney stones?. . 2022; 611 - 618. 10.31362/patd.1117026
IEEE DURAN M,Senel S,Izci Duran T,YIKILMAZ T,toksoz s "How has the COVID-19 disease affected patients with kidney stones?." , ss.611 - 618, 2022. 10.31362/patd.1117026
ISNAD DURAN, Mesut Berkan vd. "How has the COVID-19 disease affected patients with kidney stones?". (2022), 611-618. https://doi.org/10.31362/patd.1117026
APA DURAN M, Senel S, Izci Duran T, YIKILMAZ T, toksoz s (2022). How has the COVID-19 disease affected patients with kidney stones?. Pamukkale Tıp Dergisi, 15(3), 611 - 618. 10.31362/patd.1117026
Chicago DURAN Mesut Berkan,Senel Samet,Izci Duran Tugba,YIKILMAZ Taha Numan,toksoz serdar How has the COVID-19 disease affected patients with kidney stones?. Pamukkale Tıp Dergisi 15, no.3 (2022): 611 - 618. 10.31362/patd.1117026
MLA DURAN Mesut Berkan,Senel Samet,Izci Duran Tugba,YIKILMAZ Taha Numan,toksoz serdar How has the COVID-19 disease affected patients with kidney stones?. Pamukkale Tıp Dergisi, vol.15, no.3, 2022, ss.611 - 618. 10.31362/patd.1117026
AMA DURAN M,Senel S,Izci Duran T,YIKILMAZ T,toksoz s How has the COVID-19 disease affected patients with kidney stones?. Pamukkale Tıp Dergisi. 2022; 15(3): 611 - 618. 10.31362/patd.1117026
Vancouver DURAN M,Senel S,Izci Duran T,YIKILMAZ T,toksoz s How has the COVID-19 disease affected patients with kidney stones?. Pamukkale Tıp Dergisi. 2022; 15(3): 611 - 618. 10.31362/patd.1117026
IEEE DURAN M,Senel S,Izci Duran T,YIKILMAZ T,toksoz s "How has the COVID-19 disease affected patients with kidney stones?." Pamukkale Tıp Dergisi, 15, ss.611 - 618, 2022. 10.31362/patd.1117026
ISNAD DURAN, Mesut Berkan vd. "How has the COVID-19 disease affected patients with kidney stones?". Pamukkale Tıp Dergisi 15/3 (2022), 611-618. https://doi.org/10.31362/patd.1117026